Prostaglandin E1 in Outpatients With Intermittent Claudication
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01263925 |
Recruitment Status :
Completed
First Posted : December 21, 2010
Results First Posted : June 29, 2012
Last Update Posted : October 27, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stage II Peripheral Arterial Occlusive Disease Intermittent Claudication Fontaine Stage II PAOD | Drug: Alprostadil (Prostaglandin E1) Drug: Pentoxifylline Drug: Placebo to Pentoxifylline oral Drug: Placebo to Alprostadil (Prostaglandin E1) intravenous | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 561 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication |
Study Start Date : | April 2001 |
Actual Primary Completion Date : | April 2011 |
Actual Study Completion Date : | April 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Alprostadil
Alprostadil (Prostaglandin E1) intravenous and matching Placebo to Pentoxifylline oral
|
Drug: Alprostadil (Prostaglandin E1)
4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours. 4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours. Other Name: Prostavasin Drug: Placebo to Pentoxifylline oral 4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets. 4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets. |
Active Comparator: Pentoxifylline
Pentoxifylline oral and matching Placebo to Alprostadil (Prostaglandin E1) intravenous
|
Drug: Pentoxifylline
4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets. 4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets. Other Name: Trental® Drug: Placebo to Alprostadil (Prostaglandin E1) intravenous 4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours. 4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours. |
- Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline [ Time Frame: From Baseline to the end of 4 weeks of Interval Treatment (Period 2) ]The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 2 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at Baseline [ Time Frame: From Baseline to the end of 6-months Follow-up (Period 3) ]The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at Baseline [ Time Frame: From Baseline to the end of 4 weeks of Daily Treatment (Period 1) ]The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 1 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings After Period 1 [ Time Frame: From the end of 4 weeks of Daily Treatment (Period 1) to the end of 4 weeks of Interval Treatment (Period 2) ]The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 2 divided by the pain-free walking distance after Period 1 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 1 [ Time Frame: From the end of 4 weeks of Daily Treatment (Period 1) to the end of 6-months Follow-up (Period 3) ]The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance after Period 1 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 2 [ Time Frame: From the end of 4 weeks of Interval Treatment (Period 2) to the end of 6-months Follow-up (Period 3) ]The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance after Period 2 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Maximum Walking Distance After Period 1 in Comparison With the Findings at Baseline [ Time Frame: From Baseline to the end of 4 weeks of Daily Treatment (Period 1) ]The ratio of maximum walking distance was calculated by the maximum walking distance after Period 1 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings at Baseline [ Time Frame: From Baseline to the end of 4 weeks of Interval Treatment (Period 2) ]The ratio of maximum walking distance was calculated by the maximum walking distance after Period 2 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings After Period 1 [ Time Frame: From the end of 4 weeks of Daily Treatment (Period 1) to the end of 4 weeks of Interval Treatment (Period 2) ]The ratio of maximum walking distance was calculated by the maximum walking distance after Period 2 divided by the maximum walking distance after Period 1 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings at Baseline [ Time Frame: From Baseline to the end of 6-months Follow-up (Period 3) ]The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 1 [ Time Frame: From the end of 4 weeks of Daily Treatment (Period 1) to the end of 6-months Follow-up (Period 3) ]The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance after Period 1 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 2 [ Time Frame: From the end of 4 weeks of Interval Treatment (Period 2) to the end of 6-months Follow-up (Period 3) ]The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance after Period 2 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved.
- Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 1 [ Time Frame: From Baseline to the end of 4 weeks of Daily Treatment (Period 1) ]
Scores for subscales were calculated by summing non-missing item scores ranging from 1 (not at all; best possible outcome) to 4 (extremely; worst possible outcome) divided by the number of non-missing items. Hence each subscale score ranges from 1 (best possible outcome) to 4 (worst possible outcome). For subscales 'Mood' and 'Treatment expectation' five items each had to be reversed in order. Additionally, subjects were asked to assess their general health and quality of life on an ordinal scale between 0 (very good) and 10 (very poor).
Negative changes show a decrease from Baseline.
- Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 3 [ Time Frame: From Baseline to the end of 6-months Follow-up (Period 3) ]
Scores for subscales were calculated by summing non-missing item scores ranging from 1 (not at all; best possible outcome) to 4 (extremely; worst possible outcome) divided by the number of non-missing items. Hence each subscale score ranges from 1 (best possible outcome) to 4 (worst possible outcome). For subscales 'Mood' and 'Treatment expectation' five items each had to be reversed in order. Additionally, subjects were asked to assess their general health and quality of life on an ordinal scale between 0 (very good) and 10 (very poor).
Negative changes show a decrease from Baseline.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects with Peripheral Arterial Occlusive Disease (PAOD) of the lower extremity in Fontaine stage II
- Maximum walking distance on the treadmill (12 %, 3 km/h) between 30 and 150 m
- Stable Intermittent Claudication of at least 6 months standing with no acute shortening of walking distance over the past 3 months
- Stenoses or occlusions below the Femoral Bifurcation (above-knee or below-knee type) confirmed by duplex US or angiography
- Ankle/brachial index ≤ 0.90 with a decrease in systolic ankle pressure of ≥ 10 % after maximum loading (maximum walking distance on the treadmill at 3 km/h, 12 %)
- The patient is physically and mentally capable of participating in the trial
- Patient age > 40 years, male and female
- Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent
- Patient is willing and able to comply with all trial requirements
Exclusion Criteria:
- Surgical or other interventional measures performed on the affected extremity and Prostaglandin treatment within the 6 months immediately prior to the trial
- Rest pain and Necroses
- Systolic ankle pressure less than 50 mmHg
- Change in maximum walking distance during the one-week Run-in Phase of more than ± 25 % of Baseline
- Successful physical walking training within the 6 months immediately prior to the trial
- Inflammatory vascular diseases
- Polyneuropathy in Diabetes Mellitus
- Diseases limiting walking distance (Arthrosis, inflammatory diseases of the joints, neurological disease, diseases of the Vertebral Column, cardiopulmonary diseases)
- History of Pulmonary Oedema
- Myocardial infarction within the past 6 months
- Pregnancy or nursing
- Known hypersensitivity to any components of the trial medication or comparative drug
- Renal insufficiency, compensated retention (creatinine > 2.0 mg/dL)
- Severe retinal Haemorrhage
- Massive Haemorrhage
- Known existing malignant diseases
- Vasoactive concomitant medication (e.g. Naftidrofuryl, Pentoxifylline, Buflomedil, Cilostazol), or other Prostaglandins
- Untreated or uncontrolled Hypertension (systolic blood pressure ≥ 180 mmHg, diastolic blood pressure ≥ 110 mmHg)
- Previous participation of the patient in the present trial
- Participation of the patient in a trial with the same objectives within the past 6 months, or is currently participating in another trial
- Illness of the patient due to alcohol or drug-abuse within the past 6 months
- Serious illness of the patient that the investigator considers to compromise his/her participation in the trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01263925
Germany | |
Aachen, Germany | |
Bad Säckingen, Germany | |
Berlin, Germany | |
Bottrop, Germany | |
Dortmund, Germany | |
Dresden, Germany | |
Düsseldorf, Germany | |
Essen-Steele, Germany | |
Essen, Germany | |
Freiburg, Germany | |
Gaggenau, Germany | |
Görlitz, Germany | |
Hamburg, Germany | |
Hannover, Germany | |
Hattingen, Germany | |
Heidelberg, Germany | |
Homburg, Germany | |
Jena, Germany | |
Karlsbad-Lang Ensteinbach, Germany | |
Kassel, Germany | |
Krefeld, Germany | |
Köln, Germany | |
Leipzig, Germany | |
Lüneburg, Germany | |
Mannheim-Lindenhof, Germany | |
Mannheim, Germany | |
Mönchengladbach, Germany | |
München, Germany | |
Neuss, Germany | |
Nürnberg, Germany | |
Osnabrück, Germany | |
Papenburg, Germany | |
Regensburg, Germany | |
Seesen, Germany | |
Warendorf, Germany | |
Wuppertal, Germany |
Study Director: | UCB Clinical Trial Call Center | +1 877 822 9493 (UCB) |
Responsible Party: | UCB Pharma |
ClinicalTrials.gov Identifier: | NCT01263925 |
Other Study ID Numbers: |
SP0580 |
First Posted: | December 21, 2010 Key Record Dates |
Results First Posted: | June 29, 2012 |
Last Update Posted: | October 27, 2014 |
Last Verified: | May 2012 |
Alprostadil Prostaglandin E1 Prostavasin® PAOD |
Intermittent Claudication Arterial Occlusive Diseases Arteriosclerosis Vascular Diseases Cardiovascular Diseases Pentoxifylline Alprostadil Phosphodiesterase Inhibitors Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Radiation-Protective Agents Protective Agents Physiological Effects of Drugs Vasodilator Agents Free Radical Scavengers Antioxidants Urological Agents |